Brief: Mainz Biomed Establishes Partnership With Precision For Medicine To Support ColoAlert's U.S. Regulatory And Commercial Strategy
30/11/2021 08:07
Nov 30 (Reuters) - MAINZ BIOMED BV 4TO.F :
* ESTABLISHES PARTNERSHIP WITH PRECISION FOR MEDICINE TO
SUPPORT
COLOALERT'S U.S. REGULATORY AND COMMERCIAL STRATEGY
* HAS ENGAGED PRECISION FOR MEDICINE TO PROVIDE U.S.
REGULATORY
AND REIMBURSEMENT ADVISORY SUPPORT FOR COLOALERT, MAINZ'S
DIAGNOSTIC TEST FOR COLORECTAL CANCER
Source text for Eikon: ID:nEQ8TxpPNa
Further company coverage: 4TO.F
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Quantum Cyber NV
See all newsBrief: Quantum Cyber To Proceed With Pending Litigation Against Adam Gefvert
Brief: Quantum Cyber NV Files Lawsuit Against White Diamond Research, Adam Gefvert And Stocktwits, Inc. In New York Supreme Court
Quantum Cyber jumps on SpaceX stake purchase plan
Brief: Quantum Cyber Signs Loi To Acquire An Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility To Support Mass-Scale Autonomous Drone Production
Brief: Quantum Cyber NV - To Terminate ATM Sales Agreement With Maxim Effective June 7, 2026 - SEC Filing